Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
Currently Reading
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Tina Joseph Outlines Pharmacists' Role in Managing Chronic Diseases, Value-Based Care Models
May 19, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

The Rise of Orphan Drugs for Rare Diseases

Jaime Rosenberg
Since the Orphan Drug Designation program was passed in 1983, there have been over 600 orphan drug approvals, compared to less than 10 the decade before, said Stephen Jung, PharmD, BCPS, manager, drug information, MedImpact Healthcare Systems, during a session at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting.
During a session at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting held April 23-26, in Boston, Massachusetts, Stephen Jung, PharmD, BCPS, manager, drug information, MedImpact Healthcare Systems, provided an in-depth look at the Orphan Drug Designation program through the progress that’s been made, recent changes, and challenges patients continue to face.

The Orphan Drug Designation program provides orphan status to drugs and biologics defined as those intended for the safe and effective treatment, diagnosis, or prevention of rare diseases. A rare disease is defined as one that affects less than 200,000 people in the United States or one that affects more than 200,000 people but the sponsors are not expected to recover the costs of developing a new drug.

“This program was first permitted to really address an unmet need, and that need is that there was not a sufficient incentive to develop in this area, and with that, that program itself has been remarkably successful” said Jung. “If you consider that this legislation was passed in 1983, since then there have been over 600 orphan drug approvals. In contrast, during the preceding decade, there were fewer than 10.”

Jung highlighted that the number of approvals has increased remarkably over the last few the years. A significant proportion of approvals in 2017 were related to oncology, with PD-1 and PD-L1 inhibitors accounting for several indications alone.

When Scott Gottlieb, MD, was appointed FDA Commissioner, one of the major priorities he wanted to address was the backlog of orphan drug requests, explain Jung. At the time, there were over 200 designation requests under review. In less than half a year, the agency was able to work through the entire backlog. While it doesn’t mean that all the requests were approved, they were all reviewed.

Moving forward, to avoid any further accumulation of backlog, the agency aims to complete reviews within 90 days. “I think you can expect to see the approval pick up some steam,” said Jung.

Jung also highlighted another change stemming from the FDA. In December 2017, the FDA issued draft guidance that it will no longer grant orphan drug designations to pediatric subpopulations unless: the disease in the pediatric population constitutes a valid orphan subset, and the drug meets all the other criteria for orphan drug designation; or the sponsor can adequately demonstrate that the disease in the pediatric subpopulation presents differently than in the adult population, and the drug meets all other criteria for orphan designation.

Jung concluded the session by highlighting issues that patients continue to face when accessing orphan drugs. Payer sensitivity to the cost of orphan drugs continues to rise, with annual costs in the range of hundreds of thousands of dollars per patient and few (if any) available alternative therapies.

As a result, payers have changed benefit designs to manage utilization and spend through several measures: formulary restrictions and specialty tiering, the shifting from co-payments to coinsurance, and prior authorization. An analysis of reimbursement data found that orphan drugs currently have more coverage restrictions than non-orphan drugs, and prior authorization is the more commonly technique used to implement restrictions.

Related Articles

New Guidelines for Rare Disease Advocacy Groups to Navigate Interactions With Pharma
NIH Panel Features Experiences of Young Adults in Rare Disease Community
Discovery About Rare Bone Disease May Also Hold Clues About Bone Health
FDA Committee in Favor of Cannabidiol to Treat Two Rare Seizure Disorders
Patient-Reported Outcome Measures Are Key to Understanding Rare Diseases
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up